|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Burden of Clostridium difficile infection between 2010 and 2013:Trends and outcomes from an academic center in Eastern Europe显示文摘AIM:To analyze the incidence and possible risk factors in hospitalized patients treated with Clostridium difficile infection(CDI).METHODS:A total of 11751 patients were admitted to our clinic between 1 January 2010 and 1 May2013.Two hundred and forty-seven inpatients were prospectively diagnosed with CDI.For the risk analysis a 1:3 matching was used.Data of 732 patients matched for age,sex,and inpatient care period and unit were compared to those of the CDI population.Inpatient records were collected from an electronic hospital database and comprehensively reviewed.RESULTS:Incidence of CDI was 21.0/1000 admissions(2.1%of all-cause hospitalizations and 4.45%of total inpatient days).The incidence of severe CDI was 12.6%(2.63/1000 of all-cause hospitalizations).Distribution of CDI cases was different according to the unit type,with highest incidence rates in hematology,gastroenterology and nephrology units(32.9,25 and24.6/1000 admissions,respectively) and lowest rates in 1.4%(33/2312) in endocrinology and general internal medicine(14.2 and 16.9/1000 admissions)units.Recurrence of CDI was 11.3%within 12 wk after discharge.Duration of hospital stay was longer in patients with CDI compared to controls(17.6 ± 10.8d vs 12.4 ± 7.71 d).CDI accounted for 6.3%of allinpatient deaths,and 30-d mortality rate was 21.9%(54/247 cases).Risk factors for CDI were antibiotic therapy[including third-generation cephalosporins or fluoroquinolones,odds ratio(OR) = 4.559;P < 0.001],use of proton pump inhibitors(OR = 2.082,P< 0.001),previous hospitaiization within 12 mo(OR = 3.167,P < 0.001),previous CDI(OR = 15.32;P < 0.001),while presence of diabetes mellitus was associated with a decreased risk for CDI(OR = 0.484;P< 0.001).Treatment of recurrent cases was significantly different from primary infections with more frequent use of vancomycin alone or in combination(P < 0.001),and antibiotic therapy duration was longer(P < 0.02).Severity,mortality and outcome of primary infections and relapsing cases did not significantly differ.CONCLUSION:CDI was accounted for significant burden with longer hospitaiization and adverse outcomes.Antibiotic,PPI therapy and previous hospitaiization or CDI were risk factors for CDI. | Zsuzsanna Kurti Barbara D Lovasz Michael D Mandel Zoltan Csima Petra A Golovics Bence D Csako Anna Mohas Lorant Gnczi Krisztina B Gecse Lajos S Kiss Miklos Szathmari Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，21： | 6 |
| 2 | Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease显示文摘AIM:To investigate intestinal alkaline phosphatase(iAP) in the intestinal mucosa of children with inflammatory bowel disease(IBD).METHODS:Colonic biopsy samples were taken from 15 newly diagnosed IBD patients and from 10 healthy controls.In IBD patients,specimens were obtainedboth from inflamed and non-inflamed areas.The iAP mRNA and protein expression was determined by reverse transcription-polymerase chain reaction and Western blotting analysis,respectively.Tissue localization of iAP and Toll-like receptor(TLR) 4 was investigated by immunofluorescent staining.RESULTS:The iAP protein level in the inflamed mucosa of children with Crohn's disease(CD) and ulcerative colitis(UC) was significantly decreased when compared with controls(both P < 0.05).Similarly,we found a significantly decreased level of iAP protein in the inflamed mucosa in CD compared with non-inflamed mucosa in CD(P < 0.05).In addition,the iAP protein level in inflamed colonic mucosa in patients with UC was decreased compared with non-inflamed mucosa in patients with CD(P < 0.05).iAP protein levels in the non-inflamed mucosa of patients with CD were similar to controls.iAP mRNA expression in inflamed colonic mucosa of children with CD and UC was not significantly different from that in non-inflamed colonic mucosa with CD.Expression of iAP mRNA in patients with noninflamed mucosa and in controls were similar.Co-localization of iAP with TLR4 showed intense staining with a dotted-like pattern.iAP was present in the inflamed and non-inflamed mucosa of patients with CD,UC,and in control biopsy specimens,irrespective of whether it was present in the terminal ileum or in the colon.However,the fluorescent signal of TLR4 was more pronounced in the colon compared with the terminal ileum in all groups studied.CONCLUSION:Lower than normal iAP protein levels in inflamed mucosa of IBD patients may indicate a role for iAP in inflammatory lesions in IBD.Based on our results,administration of exogenous iAP enzyme to patients with the active form of IBD may be a therapeutic option. | Kriszta Molnár dám Vannay Beáta Szebeni Nóra Fanni Bánki Erna Sziksz ron Cseh Hajnalka Gyrffy Péter László Lakatos Mária Papp András Arató Gábor Veres | 2012 | World Journal of Gastroenterology2012，18，25： | 5 |
| 3 | CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells显示文摘AIM:The effects of vitamin D3 have been investigated on various tumors, including colorectal cancer (CRC). 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the enzyme that inactivates the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered to be the main enzyme determining the biological halflife of 1,25-D3. During colorectal carcinogenesis, the expression and concentration of CYP24A1 increases significantly, suggesting that this phenomenon could be responsible for the proposed efficacy of 1,25-D3 in the treatment of CRC. The aim of this study was to investigate the anti-tumor effects of vitamin D3 on the human CRC cell line Caco-2 after inhibition of the cytochrome P450 component of CYP24A1 activity. METHODS:We examined the expression of CYP24A1 mRNA and the effects of 1,25-D3 on the cell line Caco-2 after inhibition of CYP24A1. Cell viability and proliferation were determined by means of sulforhodamine-B staining and bromodeoxyuridine incorporation, respectively, while cytotoxicity was estimated via the lactate dehydrogenase content of the cell culture supernatant. CYP24A1 expression was measured by realtime reverse transcription polymerase chain reaction. A number of tetralone compounds were synthesized to investigate their CP24A1 inhibitory activity. RESULTS:In response to 1,25-D3, CYP24A1 mRNA expression was enhanced significantly, in a time- and dose-dependent manner. Caco-2 cell viability and proliferation were not influenced by the administration of 1,25-D3 alone, but were markedly reduced by coadministration of 1,25-D3 and KD-35, a CYP24A1-inhibiting tetralone. Our data suggest that the mechanism of action of co-administered KD-35 and 1,25-D3 does not involve a direct cytotoxic effect, but rather the inhibition of cell proliferation. CONCLUSION:These findings demonstrate that the selective inhibition of CYP24A1 by compounds such as KD-35 may be a new approach for enhancement of the anti-tumor effect of 1,25-D3 on CRC. | János P Kósa Péter Horváth János Wlfling Dóra Kovács Bernadett Balla Péter Mátyus Evelin Horváth Gábor Speer István Takács Zsolt Nagy Henrik Horváth Péter Lakatos | 2013 | World Journal of Gastroenterology2013，19，17： | 5 |
| 4 | New serological markers in pediatric patients with inflammatory bowel disease显示文摘The spectrum of serological markers associated with inflammatory bowel disease(IBD)is rapidly growing.Due to frequently delayed or missed diagnoses,the application of non-invasive diagnostic tests for IBD,as well as differentiation between ulcerative colitis(UC)and Crohn’s disease(CD),would be useful in the pediatric population.In addition,the combination of pancreatic autoantibodies and antibodies against Saccharomyces cerevisiae antibodies/perinuclear cytoplasmic antibody(pANCA)improved the sensitivity of serological markers in pediatric patients with CD and UC.Some studies suggested that age-associated differences in the patterns of antibodies may be present,particularly in the youngest children.In CD,most patients develop stricturing or perforating complications,and a significant numberof patients undergo surgery during the disease course.Based on recent knowledge,serum antibodies are qualitatively and quantitatively associated with complicated CD behavior and CD-related surgery.Pediatric UC is characterized by extensive colitis and a high rate of colectomy.In patients with UC,high levels of antiCBir1 and pANCA are associated with the development of pouchitis after ileal pouch-anal anastomosis.Thus,serologic markers for IBD can be applied to stratify IBD patients into more homogeneous subgroups with respect to disease progression.In conclusion,identification of patients at an increased risk of rapid disease progression is of great interest,as the application of early and more aggressive pharmaceutical intervention could have the potential to alter the natural history of IBD,and reduce complications and hospitalizations. | Márta Kovács Katalin Eszter Müller Mária Papp Péter László Lakatos Mihály Cs?ndes Gábor Veres | 2014 | World Journal of Gastroenterology2014，20，17： | 4 |
| 5 | Molecular mechanism of RNA silencing suppression mediated by p19 protein of tombusviruses显示文摘 | Lakatos L Szittya G Sihavy D | 2004 | EMBO J2004，23，4： | 1 |
| 6 | Characterization of the co-caine-and amphetamine-regulated transcript(CART)peptide gene promot-er and its activation by a cyclic AMP-dependent signaling pathway in GH3cells显示文摘 | DOMINGUEZ G LAKATOS A KUHAR M J | 2002 | J Neurochem2002，80，5： | 1 |
| 7 | Efficacy and safety of in- fliximab induction therapy in Crohn' sDisease in CentraIEurope -aHungarian nationwide obser-vational study 显示文摘 | Miheller P Lakatos P L Horv6th G | 2009 | BMC Gastroen- tero12009，9，： | 1 |
| 8 | The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis:a randomized extension to the HORIZON-Pivotal Fracture Trial(PFT)显示文摘 | Black DM Reid IR Boonen S Bucci-Rechtweg C Cauley JA Cosman F Cummings SR Hue TF Lippuner K Lakatos P Leung PC Man Z Martinez RL Tan M Ruzycky ME Su G Eastell R | | 0，，： | 1 |
| 9 | Immediate increase in aqueous humour endothelin 1 concentration and intra-ocular pressure after argon laser trabeculoplasty in the rabbit显示文摘 | Hollo G Lakatos P Vargha P | 2000 | Ophthalmologica2000，214，4： | 1 |
| 10 | Low temperature in-hibits RNA silencing -mediated defence by the control of siRNAgeneration显示文摘 | SZITTYA G SILHAVY D MOLNAR A HAVELDA Z LOVAS A LAKATOS L BANFALVI Z B'URGYAN J | 2003 | EMBO J2003，22，： | 1 |
| 11 | The Behavior of Matrix metallo- proteinase - 9 in lymphocytic colitis, collagenous colitis and ulcer - ative eolitis显示文摘 | Lakatos G Sipos F Miheller P | 2011 | Pathol Oncol Res2011，7，16： | 1 |
| 12 | The risk of lymphoma and im- munomodulators in patients with inflammatory bowel diseases:results from a population-based cohort in Eastern Europe显示文摘 | Lakatos PL Lovasz BD David G | 2013 | Journal of Crohn & colitis2013，7，5： | 1 |
| 13 | Common mutations of ATP7B in Wilson disease patients from Hungary显示文摘 | Firneisz G Lakatos PL Szalay F | 2002 | Am J Med Genet2002，108，1： | 1 |
| 14 | Elevated serum TNF-levels as a link between endothelial dysfunction and insulin resistance in normotensive obese subjects显示文摘 | Winkler G Lakatos P Salamon F | 1999 | Diabet Med1999，16，： | 1 |
| 15 | Angiogenic effects of LMWH in patients with stable coronary disease, A pilot study 显示文摘 | Quyyumi A A Diodati J G Lakatos E | 1993 | J Am Coll Cardiol1993，22，： | 1 |
| 16 | A carbon nanotube cross structure as a nanoscale quantum device 显示文摘 | Nojeh A Lakatos G W Peng S | 2003 | Nano Lett2003，，3： | 1 |
| 17 | Evaluation of the malnutrition-in-flammation score in kidney transplant recipients显示文摘 | Molnar MZ Keszei A Czira ME Rudas A UjszasziA Haromszeki B Kosa JP Lakatos P Sarvary E Beko G | 2010 | Am J Kidney Dis2010，，： | 1 |
| 18 | Extra-intestinal manifestation of IBD in Veszprem county(of Hungary):results of a 25-year follow-up study显示文摘 | Lakatos L Pandur T David G | 2003 | Orv Hetil2003，144，10： | 1 |
| 19 | Efficacy and safety ofinfliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study显示文摘 | Miheller P Lakatos PL Horvtlth G ct al | 2009 | BMC Gastroenterol2009，9，： | 1 |
| 20 | Application of constructed wetlands for wastewater treatment in Hungary显示文摘 | Lakatos G M K Kiss M Kiss | 1997 | Water Science and Technology1997，35，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员